RE:RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A DealsONCY is ready for the FDA's recently sought reforms in the accelerated approval process that would be be codified in the new Congress Spending Bill though ONCY's progress towards a registrational breast cancer study.
Consequently, Big Pharma's interest in a "FDA ready company" like ONCY has become even more profound as a result of the recently announced reforms contained in the upcoming Spending Bill that most other biotech companies have yet to prepare for.
Decmber 08, 2022 - "Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics Biotech Inc., commented, "BRACELET-1's upcoming readout represents a crucial catalyst for Oncolytics, as data from the trial are expected to pave the way for pelareorep's advancement to a registrational breast cancer study. We believe Adlai Nortye's latest data significantly de-risk this upcoming readout as they validate IND-213's positive results by confirming the ability of pelareorep plus paclitaxel to drive durable clinical responses in HR+/HER2- breast cancer patients. I'd like to thank Adlai Nortye for the productive partnership that led to these results, providing us with added enthusiasm for the outlook of our breast cancer program."
https://www.oncolyticsbiotech.com/press-releases/detail/589/oncolytics-biotechs-chinese-development-partner-adlai